Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuropathic Pain

Objective： To evaluate the analgesic efficacy of controlled-release （CR） oxycodone and gabapentin in malignant neuropathic pain （NP）. Methods： Patients with malignant NP were enrolled and baseline pain intensity （PI） was recorded. They initially took one week CR oxycodone and were allocated to two different groups at day 8 by reevaluated PI. Patients with mild pain went to CR oxycodone mono-therapy group （OO group） and took another two weeks CR oxycodone. Others went to （CR oxycodone combined gabapentin group （OG group） and received additional gabapentin. Daily doses and side effects were recorded. Results： Fifty-eight （92.06%） of the 63 enrolled patients completed the initial week＇s therapy. Twenty-two （37.93%） went to OO group and PI significantly reduced at day 15 （2.00 vs. 2.62, P=0.004）, but not improved at day 22 （1.90 vs. 2.00, P=0.54）. Thirty-six （62.07%） patients went to OG group and PI was significantly reduced at day 15 （4,47 vs. 2.94, P〈0.001）, but not improved at day 22 （2.94 vs. 2.75, P=0.136）. Mean daily dose （MDD） of CR oxycodone at day 8 was 62.64 mg. It was significantly increased at days 15 and 22 （71.43 mg vs. 62.64 rag, P=0.021; 81.90 mg vs. 71.43 mg, P=0.004） in OO group. MDD of gabapentin was significantly increased at day 22 compared to day 15 （862.50 mg vs. 993.75 mg, P〈0.001）. Constipation was occurred in 13.64% of the patients in OO group and 14.26 % in OG group. Conclusion： Malignant NP may be well controlled by oxycodone mono-therapy. Early combination with gabapentin is sensible when pain is not satisfactory relieved by oxycodone alone. The side effects of them are manageable.

Enduring alterations in hippocampal astrocytesynaptic proximity following adolescent alcohol exposure: reversal by gabapentin

Adolescent alcohol abuse is a substantive public health problem that has been the subject of intensive study in recent years.Despite reports of a wide range of effects of adolescent intermittent ethanol(AIE)exposure on brain and behavior,little is known about the mechanisms that may underlie those effects,and even less about treatments that might reverse them.Recent studies from our laboratory have indicated that AIE produced enduring changes in astrocyte function and synaptic activity in the hippocampal formation,suggesting the possibility of an alteration in astrocyte-neuronal connectivity and function.We utilized astrocyte-specific,membrane restricted viral labeling paired with immunohistochemistry to perform confocal single cell astrocyte imaging,three-dimensional reconstruction,and quantification of astrocyte morphology in hippocampal area CA1 from adult rats after AIE.Additionally,we assessed the colocalization of astrocyte plasma membrane labeling with immunoreactivity for AMPA-(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)glutamate receptor 1,an AMPA receptor subunit and established neuronal marker of excitatory synapses,as a metric of astrocyte-synapse proximity.AIE significantly reduced the colocalization of the astrocyte plasma membrane with synaptic marker puncta in adulthood.This is striking in that it suggests not only an alteration of the physical association of astrocytes with synapses by AIE,but one that lasts into adulthood-well after the termination of alcohol exposure.Perhaps even more notable,the AIE-induced reduction of astrocyte-synapse interaction was reversed by sub-chronic treatment with the clinically used agent,gabapentin(Neurontin),in adulthood.This suggests that a medication in common clinical use may have the potential to reverse some of the enduring effects of adolescent alcohol exposure on brain function.All animal experiments conducted were approved by the Duke University Institutional Animal Care and Use Committee(Protocol Registry Number A159-18-07)on July 27,2018.

A Comparative Study of Effect of Intravenous Lidocaine Infusion, Gabapentin and Their Combination on Postoperative Analgesia after Thyroid Surgery

Objective: This prospective randomized study aimed to evaluate the effect of IV lidocaine infusion or gabapentin and their combination in providing efficient analgesia after thyroid surgery. Methods: Eighty-eight patients scheduled for thyroidectomy were randomized into four equal groups (n = 22). Group P (placebo) patients received placebo capsules 1 h preoperatively and intravenous (IV) saline infusion. Group L (Lidocaine): patients received placebo capsules 1 h preoperatively and IV bolus lidocaine 1.0 mg/kg followed by infusion 2 mg/kg/h. Group G (Gabapentin) patients received 600 mg gabapentin capsules 1 h preoperatively and IV saline infusion. Group LG (Lidocaine-Gabapentin) patients received 600 mg gabapentin capsules 1 h preoperatively and IV bolus of 1.0 mg/kg lidocaine followed by infusion 2 mg/kg/h. (lidocaine or saline infusion started before induction of anesthesia and continued until the end of surgery). Intraoperative fentanyl consumption and hemodynamic changes were recorded. Postoperative total tramadol consumption, time to first analgesic request, visual analog scale (VAS) of pain, sedation level, and side effects were assessed for 24 hours. Results: (LG) group had significant lower intraoperative fentanyl and lower postoperative tramadol consumption (p < 0.001) compared to (P), (L) and (G) groups, with prolonged time of first analgesic request (p < 0.001) compared to (P) and (L) groups, and lower VAS compared to other groups (p < 0.001 or p < 0.01). There was significantly lower postoperative nausea and vomiting (PONV) in G & LG groups compared to (P) group (p < 0.01). Conclusion: The combination of preoperative gabapentin and intraoperative lidocaine infusion provided more analgesic effect than either drug alone with lower and more delayed postoperative analgesic requirements and lower VAS. (PONV) was lower in groups received gabapentin.

A Novel Spectrophotometric Method for Determination of Gabapentin in Pharmaceutical Formulations Using 2,5-Dihydroxybenzaldehyde

A highly simple, rapid, sensitive and selective method is developed for spectrophotometric determination of gabapentin in pure form as well as in pharmaceutical formulations. The method is based on the formation of a yellow Schiff base derived from the condensation of gabapentin drug (1-amino methyl) cyclo hexane acetic acid and 2,5-dihydroxybenzaldehyde (DHBA) exhibiting a maximum absorbance at 445 nm. The composition, molar absorptivity and effect of different excipient have been determined spectrophotometrically. Under optimized experimental conditions, Beer’s law is obeyed in the concentration range 2.57 - 37.25 μg/ml. The method is validated with respect to accuracy, precision, limit of detection and limit of quantification. The Sandell sensitivity, correlation coefficient and regression equation are calculated. The equilibrium constant and free energy change using Benesi-Hildebrand plot are also determined. The Schiff base derived from condensation of gabapentin with DHBA is also synthesized and characterized. The condensation reaction mechanism has been proposed.

Effects of Pre-Operative Single Dose Gabapentin on Postoperative Pain Following Total Abdominal Hysterectomy: A Dose Finding Study

Background & Aims: The multimodal analgesia provides superior pain relief and reduces opioid consumption and its side effects. Gabapentin has been used successfully in multi-modal analgesia in different doses. We designed a double-blind randomized control trial to find the minimal effective dose of gabapentin in multimodal analgesia for postoperative pain following total abdominal hysterectomy. Material & Methods: After informed consent, total of 87 patients were randomly assigned to A, B & C groups to receive gabapentin orally 300 mg, 600 mg, and 900 mg respectively one to two hours before surgery. Postoperatively pain was managed by patient-controlled analgesia (PCA) using pethidine. Pain score, opioid consumption, and side effects of gabapentin were monitored. Rescue analgesia was given and monitored. Results: There was no statistically significant difference among the groups with respect to age, weight, height, pethidine consumption, and rescue analgesia. Mean pain scores were statistically insignificant at baseline, 8, 12, and 24 hours postoperatively. Only at 4 hours, the highest pain score (mean) was found in group A, which is statistically significant. The side effects of gabapentin like nausea, vomiting, somnolence, and dizziness were also statistically insignificant. Conclusion: A single preoperative oral gabapentin 300 mg was found to be minimal effective dose in multimodal analgesic regimen for reducing post-operative pain and analgesic requirement following total abdominal hysterectomy.

Improvement in the Stability of Gabapentin by the Complexation of Gabapentin with Different Metal Ions: a DFT Study

Gabapentin undergoes intramolecular cyclization by alkylamine nucleophilic attacking on carboxylate carbonyl. And the above self-dehydration condensation can produce gabapentin lactam which has some toxic effects. Therefore, in order to decrease the above subsidiary reaction, the effects of several metal ions on the reaction mechanism and the potential barriers of self-dehydration condensation of gabapentin are analyzed. Each molecular structure of gabapentin in the presence of several metal ions is optimized using the density functional theory(DFT) with B3LYP method at the 6-311+G(d,p) basis set level. And its geometric and thermodynamic parameters are also investigated. The calculated results showed that gabapentin can form stable complexes with divalent metal ions and exhibit the highest affinity for small and highly charged metal cations. The binding ability of these metal ions with gabapentin ranks in an order of Fe^2+>Zn^2+> Mg^2+> Ca^2+> Na^+> K^+. Besides, the potential barriers of subsidiary reaction of gabapentin increase obviously in the presence of several metal ions than that of free gabapentin. This means that the above metal ions can inhibit effectively the intramolecular cyclization of gabapentin.

Gabapentin for the treatment of behavioral and psychological symptoms of dementia

Objective: To examine the efficacy of gabapentin for the treatment of behavioral and psychological symptoms of dementia (BPSD). Design: A retrospective chart review. Settings: Tertiary care geriatric psychiatry inpatient unit. Participants: 230 patients with BPSD. Measurements: The socio-demographic information, type of behaviors, co-morbid psychiatric and medical diagnoses, daily doses of medications and side-effects were recorded. Results: Of the 230 patients, 22 were treated with gabapentin. Twenty of these patients were on a combination of gabapentin and an antipsychotic medication while two patients were treated with gabapentin monotherapy. Eighteen of the 20 patients in the combination group tolerated the treatments with little or no side effects as did the two patients in the monotherapy group. Conclusions: Gabapentin may be a safe option for the treatment of BPSD in combination with antipsychotic medications. Gabapentin may also be effective as monotherapy in certain patients with BPSD.

Efficacy of gabapentin for low back pain at a tertiary hospital: A prospective observational study

Objective:To assess the efficacy of gabapentin in the treatment of low back pain patients.Methods:This prospective observational study was conducted over 6 months to assess the efficacy of gabapentin in patients suffering from low back pain.Past medical history,pain severity by Visual Analogue scale(VAS)and sleep quality by Pittsburgh Sleep Quality Index(PQSI)were collected.VAS scores and PQSI scores before and after gabapentin treatment were compared,and gabapentin satisfaction post treatment were recorded.Results:This study included 100 low back pain patients with 65 males and 35 females,and the mean age was(39.0±10.5)years.The commonest presentation was non-radiating low back pain(40%).The mean VAS score and the mean PQSI score in the study before treatment were 7.70±1.91 and 10.95±5.02,respectively.After treatment with gabapentin,the mean VAS score and the mean PQSI score decreased to 2.75±1.79 and 4.90±2.20,respectively,and the differences before and after the treatment were significantly different(both P=0.001).Overall,62%of the patients were extremely satisfied with gabapentin because they reported no adverse drug reaction.Besides,31%of the patients were satisfied and 7%were strongly dissatisfied with the therapy.Conclusion:Gabapentin can improve sleep quality and reduce lower back pain as measured by the VAS and PQSI.The efficacy of this drug is relatively good,but further improvement is required.

Transdermal Delivery of Gabapentin: Effect of Cosolvent and Microemulsion on Permeation through the Rat Skin

The objective of the present study was to examine the influence of cosolvent system and micro-emulsion formulation on in-vitro skin permeation of gabapentin, furthermore, to characterize the physicochemical properties of drug-loaded oil-in-water (o/w) and water-in-oil (w/o) cremophor 40-based microemulsions in comparison to the blank counterparts. The cosolvent system prepared by homogenous mixing is composed of ethanol-water and propylene glycol-water mixture (90:10, 80:20, 70:30 v/v) respectively. The microemulsion consisted of coconut oil, water and mixture of cremophor 40 (surfactant) and ethanol (cosurfactant) and was prepared by aqueous phase titration method. Physicochemical properties of microemulsions were determined using reported procedures. Transdermal flux for gabapentin was studied in-vitro using modified Franz diffusion cells. The physicochemical properties of drug-loaded microemulsions and their blank counterparts were generally alike, however, slight variation in pH and viscosity was observed probably due to the intrinsic properties of the drug. The ethanol-water system (70:30 v/v) gave higher flux for gabapentin when compared to propylene glycol-water system (70:30 v/v). The w/o microemulsion formulations resulted in, higher flux for gabapentin when compared to o/w formulations. FTIR spectra of the untreated stratum corneum, when compared to cosolvent system and microemulsion treated stratum corneum, suggest the mechanism of permeation to be disruption of lipid bilayers and keratin denaturation of the stratum corneum. The results show that incorporation of gabapentin into microemulsions did not change the microemulsion type. The in vitro permeation data obtained from experimental work suggest that the cosolvent system (ethanol-water 70:30 v/v) and w/o microemulsion formulations respectively, can be successfully used as potential vehicles in developing transdermal therapeutic systems for gabapentin.

Comparative Study between the Benefit of Pre-Emptive Pregabalin and Gabapentin on Acute Postoperative Pain for Elective Gynecological Surgery

Gabapentin, and pregabalin had been used in analgesic field some studies. This double blind randomized clinical trial was conducted to evaluate the pre-emptive use of gabapentin 900 mg and pregabalin 300 mg in reducing postoperative pain. Methods: A total number of 75 patients undergoing lower gynecological procedures were prospectively randomized, into three groups (group A, B and C), each group including 25 patients with total 75 patients. Pregabalin, gabapentin or placebo, the pain was assessed on a visual analogue scale (VAS) at 0, 6, 12, 18 & 24 hours postoperatively. Duration of effective analgesia was documented, and administration of extra analgesic doses of meperedine required in the first 24 hours. Results: Patients in the gabapentin or pregabalin had significantly lower VAS scores at 6, 12, 18 and 24 hours, than those in the placebo group. As for rescue analgesia with mepredine consumed in the gabapentin, and pregabalin were significantly less than in the placebo. As for the complications, both drugs had increased incidence of nausea, vomiting and dizziness postoperatively, while no significance was found between all groups as regard hypotension, bradycardia and shivering. Conclusion: Preoperative use of pregabalin or gabapentin provides comparable but significant prolonged postoperative analgesia, less nausea and vomiting compared to placebo after gynecological surgeries. However, it was associated with increased incidence of postoperative dizziness.

Effect of Pregabalin and Gabapentin on Nociceptive Behaviors Induced by Spinal Nerve Ligation

Pain is defined as an unpleasant sensory and emotional experience, associated with actual or potential tissue damage. According to its neurobiological mechanism, pain is classified into nociceptive, inflammatory, dysfunctional, and neuropathic. Neuropathic pain (NP) is caused by a lesion or disease of the somatosensory nervous system. Both pregabalin and gabapentin are pharmaceuticals used as validation drugs in experimental models of NP. Pregabalin was shown to produce significant antihyperalgesic and antiallodynic effects. Gabapentin is used as a reference compound for new analgesics and reduces tactile allodynia in rats. The aim of this work is to evaluate pregabalin and gabapentin effects on nociceptive behaviors induced by spinal nerve ligation (SNL). Female Wistar rats of 140 - 160 g were used, divided into five groups: Naive, SHAM, SNL rats treated with saline solution, SNL rats treated with pregabalin 30 mg/kg p.o., SNL rats treated with gabapentin 300 mg/kg p.o. Nociceptive behaviors were determined by the up and down method. In the establishment of SNL-induced allodynic behavior, a reduction in paw withdrawal threshold was observed in the time course, which was present from day 1 and it was maintained for 28 days post-ligation. With the administration of pregabalin and gabapentin, anti-allodynic behavior was observed in the time course and in the areas under the curve (AUC) of the time course of anti-allodynic behavior, significant difference was observed between pregabalin, and gabapentin groups compared to vehicle with a value of p < 0.0001. The results showed pregabalin and gabapentin induce an antinociceptive effect in rats subjected to SNL.

理想的抗癲痫新药—GABAPENTIN

1992年9月初在英国格拉斯哥欧洲癫痫病年会上,药物学家和神经病学家介绍了一种治疗癫痫的新药—GABAPENTIN。该药由帕克、戴维斯发明,预计明年批准使用。英国大卫.查得卫科教授指出:“

Preoperative Gabapentin Dosage Relationship to Length of Stay in Post-Anesthesia Care Unit in Patients Undergoing Pelvic and Breast Surgery

Background: Gabapentin is routinely prescribed preoperatively to decrease postoperative pain intensity. It is included in the enhanced recovery after surgery (ERAS) recommendations. Objective: To analyze correlation of gabapentin dosage and post anesthesia care unit (PACU) length of stay (LOS) and cost. Study Design: A retrospective chart review of patients who underwent general anesthesia and received preoperative oral gabapentin from June 2017 to August 2017 for pelvic and breast procedures. The main outcome was correlation between PACU LOS and gabapentin dosage in the outpatients. Financial analysis was performed to assess the cost to the hospital associated with increased LOS. Results: Of the 636 patients, 405 patients received 300 mg and 231 patients received 100 mg gabapentin. Mean dosage per kg (mg/kg ± SD) was 3.12 ± 1.51 (range: 0.86 to 6.12). PACU LOS was 96 ± 77 (minutes ± SD) in patients receiving 100 mg and 120 ± 96 in patients receiving 300 mg capsule (p = 0.001). Linear regression analysis, failed to show a statistically significant correlation between per kg dosage and PACU LOS (p = 0.13). Using multiple regression analysis, we calculated the correlation coefficient to be +1.71 minutes per 1mg/kg gabapentin (95% CI: -3.75 to +7.10, p = 0.54) after adjusting for confounders. Adding 3 mg/kg to pre-op gabapentin dosage of all outpatients cost on average, an extra $9794 per month in this cohort. Conclusion: Every 1mg/kg increase in gabapentin dosage adds an estimated 7.1 minutes to PACU LOS. A 3 mg/kg increase in gabapentin adds estimated 22 additional minutes in PACU LOS. Unfortunately, increase LOS is associated with increased hospital costs.

Astellas在日本递交gabapentin enacarbi的新药申请

Astellas Pharma公司最近已向日本药品与医疗器械审批机构（PMDA）提交了ASP8825（gabapentin enacarbil）（或称作XP13512）（I）的新药申请，该药用于治疗不宁腿综合征（RLS）。

加巴喷丁联合短时程神经电刺激治疗头面部带状疱疹性神经痛的临床效果

目的观察加巴喷丁联合短时程神经电刺激治疗头面部带状疱疹性神经痛的效果和安全性。方法选取2019年8月—2023年1月广州医科大学附属第六医院收治的70例急性期或亚急性期带状疱疹性神经痛患者作为研究对象,随机分为对照组与观察组,各35例。对照组给予加巴喷丁治疗,观察组同样剂量加巴喷丁联合短时程神经电刺激,均治疗4周。于患者治疗前(T_(0))及治疗后1周(T_(1))、2周(T_(2))、4周(T_(3))、2个月(T_(4))、3个月(T_(5))、6个月(T_(6))比较视觉模拟评分(visual analogue scale,VAS)、睡眠质量评分、不良反应,对患者的临床疗效进行评估。结果2组治疗后不同时间点VAS评分均低于治疗前(P<0.001);且观察组治疗后不同时间点VAS评分低于对照组,差异有统计学意义(P<0.05)。2组治疗后不同时间点睡眠质量评分均高于治疗前(P<0.001);观察组治疗后相同时间点睡眠质量评分高于对照组,但差异无统计学意义(P>0.05)。对照组不良反应总发生率为28.57%(10/35),观察组不良反应总发生率为5.71%(2/35),差异有统计学意义(P<0.05)。结论加巴喷丁联合短时程神经电刺激治疗头面部带状疱疹性神经痛能减轻患者疼痛程度,改善睡眠质量且安全性高,总体疗效更优。

黄芪桂枝五物汤联合加巴喷丁治疗尿毒症不宁腿综合征患者的效果

目的:探讨黄芪桂枝五物汤联合加巴喷丁治疗尿毒症不宁腿综合征(RLS)的效果。方法:选取2022年6月—2023年6月湖南中医药大学第一附属医院肾脏内科尿毒症RLS患者60例为研究对象,随机分为对照组和观察组,各30例。对照组使用加巴喷丁治疗,观察组在对照组基础上加用黄芪桂枝五物汤治疗。比较两组临床疗效、睡眠质量、症状指标及情绪状态。结果:观察组总有效率高于对照组,差异有统计学意义(P=0.006);治疗后,两组睡眠质量、睡眠效率、入睡时间、睡眠时间、睡眠障碍、催眠药物、日间功能障碍评分均降低,观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组国际下肢不宁腿综合征等级评估量表、汉密尔顿焦虑量表、汉密尔顿抑郁量表评分降低,观察组低于对照组,差异有统计学意义(P<0.05)。结论:黄芪桂枝五物汤联合加巴喷丁治疗尿毒症RLS的效果确切,能有效缓解症状,改善睡眠及心理状况。

Endogenous enkephalin does not contribute to the cerebral anti-hyperalgesic action of gabapentin

The aim of this study was to investigate the role of endogenous enkephalin in the cerebral antihyperalgesic action of gabapentin.Neuropathic pain models and antihyperalgesic effect of gabapentin were confirmed by the presentation and changes of mechanical allodynia and thermal hyperalgesia of operated mouse hind paws.The results suggested that endogenous enkephalin may not be involved in the antihyperalgesic effect of gabapentin.

加巴喷丁联合甲钴胺治疗脑梗死继发不宁腿综合征的临床研究

目的探讨加巴喷丁联合甲钴胺对脑梗死继发不宁腿综合征的治疗效果。方法纳入2022年1月—2023年12月在南阳市第一人民医院接受治疗的脑梗死继发不宁腿综合征患者62例,根据治疗方式分为对照组(n=30,甲钴胺)和观察组(n=32,加巴喷丁联合甲钴胺)。治疗前和治疗后评估两者患者不宁腿症状、焦虑情绪、抑郁情绪、睡眠质量,分析血红蛋白水平与不宁腿症状相关性。结果治疗前,两组患者不宁腿症状评分、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分和匹兹堡睡眠质量指数(PSQI)评分均相近,差异无统计学意义(均P>0.05);治疗后,观察组和对照组不宁腿症状评分[分别为(8.35±2.91)分vs(18.83±3.74)分]、HAMA评分[分别为(8.91±2.10)分vs(16.23±2.78)分]、HAMD评分[分别为(7.47±2.92)分vs(17.76±2.34)分]和PSQI评分[分别为(6.35±1.36)分vs(13.83±1.64)分]比较,差异均有统计学意义(均P<0.05)。53例(85%)患者血红蛋白水平正常,9例(15%)患者血红蛋白水平偏低。结论加巴喷丁联合甲钴胺对脑梗死继发不宁腿综合征可能具有更好的治疗效果,值得在临床中进一步大样本研究。

加巴喷丁联合依帕司他治疗痛性糖尿病周围神经病变的效果

目的探究加巴喷丁联合依帕司他、甲钴胺治疗痛性糖尿病周围神经病变(painful diabetic peripheral neuropathy,PDPN)的疗效。方法选取96例PDPN患者,用随机分组法分为观察组(n=42)与对照组(n=54),对照组用加巴喷丁联合甲钴胺治疗,观察组在对照组治疗的基础上加用依帕司他。观察2组患者用药后的神经传导速度、视觉模拟评分(visual analogue scale,VAS)、不良反应发生率、生活质量和临床疗效。结果治疗3、6周后,观察组的VAS显著低于对照组(P<0.05)。治疗6周后,2组运动神经传导速度和感觉神经传导速度均有显著提升;且观察组的运动神经传导速度和感觉神经传导速度均显著快于对照组(P<0.05)。治疗后,观察组(1.85%)与对照组(4.76%)不良反应发生率比较差异无统计学意义(P>0.05)。治疗6周后,观察组(95.23%)与对照组(90.73%)的总有效率比较差异无统计学意义(P>0.05)。治疗6周后,2组的生理、心理、社会、疾病和满意度各维度得分均显著高于治疗前,且观察组的得分显著高于对照组(P<0.05)。结论加巴喷丁联合依帕司他、甲钴胺治疗可缓解PDPN患者的疼痛,改善神经功能,提高患者日常生活质量,值得临床推广。

加巴喷丁联合运动训练在维持性血液透析合并不宁腿综合征患者中的应用

目的:探讨加巴喷丁联合运动训练治疗维持性血液透析(MHD)合并不宁腿综合征(RLS)的临床效果。方法:选取2022年1—10月萍乡市人民医院收治的80例MHD合并RLS患者作为研究对象,按照封闭信封法随机分为常规组(n=40)与联合组(n=40)。常规组患者于每日睡前服用加巴喷丁,联合组在常规组基础上联合运动训练,两组均持续治疗3个月。比较两组临床疗效,评估两组病情严重程度[国际不安腿综合征研究组(IRLSSG)评分]、睡眠质量[匹兹堡睡眠质量指数(PSQI)]、失眠情况[阿森斯失眠量表(AIS)]、疼痛情况[视觉模拟评分法(VAS)]及生活质量[健康调查量表12(SF-12)]。结果:联合组整体疗效和总有效率均明显优于常规组(P<0.05),且联合组治疗3个月后SF-12评分高于常规组(P<0.05);治疗1、2、3个月后,两组IRLSSG、PSQI、AIS、VAS评分较治疗前均有显著降低,且联合组均低于常规组(P<0.05)。结论:采取加巴喷丁联合运动训练治疗MHD合并RLS患者可取得良好临床效果,患者失眠状况明显好转,睡眠质量得以明显改善,生活质量明显提高。